VRE and MRSA Antibiotic Market

Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person?s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn?s umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
VRE and MRSA Antibiotic Market contains market size and forecasts of VRE and MRSA Antibiotic in global, including the following market information:
Global VRE and MRSA Antibiotic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global VRE and MRSA Antibiotic Market Sales, 2017-2022, 2023-2028, (M Units)
Global top five VRE and MRSA Antibiotic companies in 2021 (%)
The global VRE and MRSA Antibiotic market was valued at 4173 million in 2021 and is projected to reach US$ 5428.1 million by 2028, at a CAGR of 3.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Vancomycin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of VRE and MRSA Antibiotic include Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical and North China Pharmaceutical and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the VRE and MRSA Antibiotic manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global VRE and MRSA Antibiotic Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global VRE and MRSA Antibiotic Market Segment Percentages, by Type, 2021 (%)
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
Global VRE and MRSA Antibiotic Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global VRE and MRSA Antibiotic Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global VRE and MRSA Antibiotic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global VRE and MRSA Antibiotic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies VRE and MRSA Antibiotic revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies VRE and MRSA Antibiotic revenues share in global market, 2021 (%)
Key companies VRE and MRSA Antibiotic sales in global market, 2017-2022 (Estimated), (M Units)
Key companies VRE and MRSA Antibiotic sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm